S'abonner

miR-200a-3p-enriched MSC-derived extracellular vesicles reverse erectile function in diabetic rats by targeting Keap1 - 23/07/24

Doi : 10.1016/j.biopha.2024.116964 
Jing Zhang a, 1, Danfeng Zhao c, 1, Zhenjie Zang b, Zheng Ruan d, e, Qiang Fu b, c, f, , 2 , Keqin Zhang b, , 2
a Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China 
b Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China 
c College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250199, China 
d Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan 250021, China 
e Department of Urology, Tai’an City Central Hospital, Tai’an 271099, China 
f Key Laboratory of Urinary Diseases in Universities of Shandong, Shandong First Medical University, Jinan 250021, China 

Corresponding author at: Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinan250021China⁎⁎Corresponding author.

Abstract

Background

The administration of mesenchymal stem cells (MSCs) through intracavernous injection is a potential therapeutic approach for managing diabetes mellitus-induced erectile dysfunction (DMED). However, pulmonary embolism and tumorigenicity are fatal adverse events that limit the clinical application of MSCs. In this study, we examined the therapeutic efficacy and potential mechanism of MSC-derived extracellular vesicles (MSC-EVs).

Methods

In this study, forty 8-week-old male Sprague-Dawley (SD) rats were utilised. In the control group, ten rats were administered an intraperitoneal injection of PBS. STZ (60 mg/kg) was intraperitoneally injected into the remaining rats to establish a diabetes mellitus (DM) model. Afterwards, the diabetic rats were divided into three groups at random: the DM group (intracavernosal injection of PBS), the EVs group (intracavernosal injection of MSC-EVs), and the EVs-200a group (intracavernosal injection of miR-200a-3p-enriched extracellular vesicles). Erectile function was determined by measuring intracavernous pressure in real time and utilising electrical stimulation of the cavernous nerves. The smooth muscle content was evaluated through the investigation of penile tissue using immunofluorescence staining, Masson's trichrome staining, and western blotting after euthanasia. Superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione (GSH) levels in the corpus cavernosum were measured via ELISA. In vitro, hydrogen peroxide (H2O2) was used to induce oxidative stress. The viability of corpus cavernosum smooth muscle cells (ccSMCs) incubated with or without H2O2 was measured using a CCK8 assay. Flow cytometry was used to assess the levels of reactive oxygen species (ROS) and apoptosis in ccSMCs. Furthermore, a dual-luciferase reporter assay was performed to validate the relationship between miR-200a-3p and Keap1.

Results

Reversal of erectile function was observed in the EVs groups, especially in the EVs-200a group. DM increased the MDA level and decreased the SOD and GSH levels. In the DM group, the expression of alpha-smooth muscle actin (α-SMA) and smooth muscle 22 alpha (SM22α) was decreased, and the expression of osteopontin (OPN) was increased. Western blotting revealed decreased Nrf2, HO-1, and Bcl2 expression and increased Keap1, Bax and cleaved caspase3 expression in the cavernous tissue. miR-200a-3p-enriched extracellular vesicles (EVs-200a) reversed these changes and inhibited the loss of smooth muscle content and cavernous fibrosis. In vitro, H2O2 induced high ROS levels in ccSMCs and increased apoptosis, and these effects reversed by EVs-200a. H2O2 reduced Nrf2, HO-1, and Bcl2 expression and increased Keap1, Bax and cleaved caspase-3 expression, and these effects were reversed by MSC-EVs, especially EVs-200a. The of dual-luciferase reporter assay results indicated that miR-200a-3p directly targeted Keap1 in a negative manner.

Conclusion

MSC-EVs, especially EVs-200a, alleviated erectile dysfunction in diabetic rats through the regulation of phenotypic switching, apoptosis and fibrosis. Mechanistically, miR-200a-3p targeted the Keap1/Nrf2 pathway to attenuate oxidative stress in diabetic rats.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




Le texte complet de cet article est disponible en PDF.

Highlights

miR-200a-3p-enriched MSC-EVs offer a promising cell-free therapy for DMED.
MSC-EVs regulate ccSMC phenotypic switch, apoptosis, and fibrosis, preserving their function.
Mechanistically, miR-200a-3p modulates Keap1/Nrf2 pathway to reduce oxidative stress.

Le texte complet de cet article est disponible en PDF.

Keywords : Erectile dysfunction, Stem cells, Extracellular vesicles, Diabetes mellitus


Plan


© 2024  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 177

Article 116964- août 2024 Retour au numéro
Article précédent Article précédent
  • Design and evaluation of a bilayered dermal/hypodermal 3D model using a biomimetic hydrogel formulation
  • Carlos Chocarro-Wrona, Julia López de Andrés, Pablo Rioboó-Legaspi, Paula Pleguezuelos-Beltrán, Cristina Antich, Juan De Vicente, Patricia Gálvez-Martín, Elena López-Ruiz, Juan Antonio Marchal
| Article suivant Article suivant
  • Effective suppression of tumor growth and hepatic metastasis of neuroblastoma by NKT-stimulatory phenyl glycolipid
  • Tai-Na Wu, Jung-Tung Hung, Tsai-Hsien Hung, Ya-Hui Wang, Jen-Chine Wu, Alice L. Yu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.